TW
Thomas W. Flaig
Likely Co-Founder / Key Advisor (Vice Chancellor for Research, CU Anschutz)
Aurora OncologyTherapeutic Areas
Aurora Oncology Pipeline
| Drug | Indication | Phase |
|---|---|---|
| DAB389EGF (EGF-toxin fusion) | Bladder Cancer (non-muscle-invasive) | Pre-clinical |
| EGFR-targeted Gold Nanoparticles | Bladder Cancer (theranostic imaging & ablation) | Pre-clinical |
| Non-invasive EGFR Diagnostic Test | Bladder Cancer (companion diagnostic) | Research |